tiprankstipranks
Advertisement
Advertisement

VTGN Stock Latest News

VistaGen Therapeutics Appoints Douglas Williamson to Board
Company AnnouncementsVistaGen Therapeutics Appoints Douglas Williamson to Board
1d ago
8K
VTGN
VistaGen pivots fasedienol toward long-term anxiety treatment
PremiumCompany Announcements
VistaGen pivots fasedienol toward long-term anxiety treatment
1M ago
8K
VTGN
Vistagen announces fasedienol did not achieve primary endpoint
PremiumThe Fly
Vistagen announces fasedienol did not achieve primary endpoint
1M ago
VTGN
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
PremiumCompany Announcements
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
2M ago
VTGN
VistaGen Reaches Key Safety Milestone for Fasedienol Program
PremiumCompany Announcements
VistaGen Reaches Key Safety Milestone for Fasedienol Program
2M ago
8K
VTGN
Vistagen announces fasedienol achieves minimum patient exposures
PremiumThe FlyVistagen announces fasedienol achieves minimum patient exposures
2M ago
VTGN
VistaGen Appoints New Chief Medical Officer to Advance Pipeline
Premium
Company Announcements
VistaGen Appoints New Chief Medical Officer to Advance Pipeline
2M ago
8K
VTGN
Vistagen appoints Angelov as Chief Medical Officer
Premium
The Fly
Vistagen appoints Angelov as Chief Medical Officer
2M ago
VTGN
VistaGen Reports Positive Long-Term Data for Fasedienol
PremiumCompany Announcements
VistaGen Reports Positive Long-Term Data for Fasedienol
3M ago
8K
VTGN
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
PremiumThe Fly
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
3M ago
VTGN
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
PremiumCompany Announcements
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
3M ago
8K
VTGN
Vistagen announces completion of last patient visit in PALISADE-4 study
PremiumThe Fly
Vistagen announces completion of last patient visit in PALISADE-4 study
3M ago
VTGN
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
PremiumCompany AnnouncementsVistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
3M ago
8K
VTGN
AbCellera target is profile more attractive than Vistagen, says JonesResearch
Premium
The Fly
AbCellera target is profile more attractive than Vistagen, says JonesResearch
3M ago
ABCL
VTGN
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
Premium
The Fly
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
3M ago
VTGN
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
PremiumCompany Announcements
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
4M ago
8K
VTGN
VistaGen Faces Nasdaq Audit Committee Compliance Setback
PremiumCompany Announcements
VistaGen Faces Nasdaq Audit Committee Compliance Setback
4M ago
8K
VTGN
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
PremiumCompany Announcements
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
5M ago
8K
VTGN
VistaGen Announces Workforce Reduction to Extend Cash Runway
PremiumCompany Announcements
VistaGen Announces Workforce Reduction to Extend Cash Runway
5M ago
8K
VTGN
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
PremiumClass ActionVISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
5M ago
VTGN
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
Premium
Market News
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
5M ago
VTGN
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
Premium
Class Action
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
5M ago
VTGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >